Skip to main content

and
  1. Article

    Open Access

    Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D

    Affecting about 1 in 12 Americans annually, depression is a leading cause of the global disease burden. While a range of effective antidepressants are now available, failure and relapse rates remain substantia...

    D E Adkins, S L Clark, K Åberg, J M Hettema, J Bukszár in Translational Psychiatry (2012)

  2. No Access

    Article

    Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs

    Understanding individual differences in the susceptibility to metabolic side effects as a response to antipsychotic therapy is essential to optimize the treatment of schizophrenia. Here, we perform genomewide ...

    D E Adkins, K Åberg, J L McClay, J Bukszár, Z Zhao, P Jia in Molecular Psychiatry (2011)

  3. No Access

    Article

    Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics

    Schizophrenia is an often devastating neuropsychiatric illness. Understanding the genetic variation affecting response to antipsychotics is important to develop novel diagnostic tests to match individual schiz...

    J L McClay, D E Adkins, K Åberg, S Stroup, D O Perkins in Molecular Psychiatry (2011)